Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/26 cls
Gilead Sciences Inc. (NASDAQ:GILD) Baird Brian Skorney Downgrade Neutral (from outperform) 4% $62.57
In his downgrade, Skorney said "now that Gilead's market cap is knocking on $100 billion, it's tough for us to find what isn't already priced in." Last week, the biotech reported 2Q13 EPS that met the Street's estimate and revenues that beat the consensus estimate. Skorney raised his target to $65 from $55 based on a discounted

Read the full 974 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers